Cannabinoids as novel anti-inflammatory drugs

Future Medicinal Chemistry

Volumn 1, Issue 7, 2009, Pages 1333-1349

  Nagarkatti, Prakash ^a   Pandey, Rupal ^a   Rieder, Sadiye Amcaoglu ^a   Hegde, Venkatesh L ^a   Nagarkatti, Mitzi ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AJULEMIC ACID; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABIS; CHEMOKINE; CYTOKINE; DEXANABINOL; GAMMA INTERFERON; NABILONE; RIMONABANT; TETRAHYDROCANNABINOL;

ALLERGIC ASTHMA; ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; CELL POPULATION; COLITIS; COLON CANCER; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; LIVER INJURY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SPLEEN; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; THYMUS; UNSPECIFIED SIDE EFFECT; UPREGULATION; UVEORETINITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CANNABINOIDS; CHEMOKINES; CYTOKINES; HUMANS; IMMUNOSUPPRESSION; MODELS, BIOLOGICAL; RECEPTORS, CANNABINOID; T-LYMPHOCYTES, REGULATORY; TETRAHYDROCANNABINOL;

EID: 77953451267     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.93     Document Type: Review

References (130)

1. Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer 3, 745-755 (2003).
2. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J. Clin. 52, 72-91 (2002).
3. Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 22, 291-324 (2008).
4. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323, 16-21 (2001).
5. Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J. Neuroimmunol. 166, 3-18 (2005).
6. Mackie K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 46, 101-122 (2006).
7. Stefano GB, Liu Y, Goligorsky MS. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J. Biol. Chem. 271, 19238-19242 (1996).
8. Devane WA, Hanus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949 (1992).
9. Mechoulam R, Ben-Shabat S, Hanus L et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50, 83-90 (1995).
10. Sugiura T, Kondo S, Sukagawa A et al. 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215, 89-97 (1995).
11. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 83-87 (1996).
12. Kaczocha M, Glaser ST, Deutsch DG. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl Acad. Sci. USA 106, 6375-6380 (2009).
13. Rodriguez De Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcoholism 40, 2-14 (2005).
14. Hengartner MO. The biochemistry of apoptosis. Nature 407, 770-776 (2000).
15. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2, 277-288 (2002).
16. Zhu W, Friedman H, Klein TW. D9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J. Pharmacol. Exp. Ther. 286, 1103-1109 (1998).
17. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS. D(9)- tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J. Pharmacol. Exp. Ther. 302, 451-465 (2002).
18. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol. 173, 2373-2382 (2004).
19. Lu T, Newton C, Perkins I, Friedman H, Klein TW. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J. Pharmacol. Exp. Ther. 319, 269-276 (2006).
20. Lee CY, Wey SP, Liao MH et al. A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells. Int. Immunopharmacol. 8, 732-740 (2008).
21. Bidinger B, Torres R, Rossetti RG et al. Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clin. Immunol. 108, 95-102 (2003).
22. Lombard C, Nagarkatti M, Nagarkatti P. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin. Immunol. 122, 259-270 (2007).
23. Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide- induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 67, 829-836 (2002).
24. Croxford JL, Pryce G, Jackson SJ et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J. Neuroimmunol. 193, 120-129 (2008).
25. Klein TW, Newton CA, Nakachi N, Friedman H. D9-tetrahydrocannabinol treatment suppresses immunity and early IFN-g, IL-12, and IL-12 receptor b 2 responses to Legionella pneumophila infection. J. Immunol. 164, 6461-6466 (2000).
26. Srivastava MD, Srivastava BI, Brouhard B. D9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40, 179-185 (1998).
27. Derocq JM, Jbilo O, Bouaboula M, Segui M, Clere C, Casellas P. Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J. Biol. Chem. 275, 15621-15628 (2000).
28. Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29, 58-69 (2000).
29. Smith SR, Terminelli C, Denhardt G. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J. Pharmacol. Exp. Ther. 293, 136-150 (2000).
30. Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res. Ther. 8(Suppl. 2), S5 (2006).
31. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum. 41, 163-170 (1998).
32. Parker J, Atez F, Rossetti RG, Skulas A, Patel R, Zurier RB. Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol. Int. 28, 631-635 (2008).
33. Rajesh M, Pan H, Mukhopadhyay P et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J. Leukoc. Biol. 82, 1382-1389 (2007).
34. Selvi E, Lorenzini S, Garcia-Gonzalez E et al. Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin. Exp. Rheumatol. 26, 574-581 (2008).
35. Valk P, Verbakel S, Vankan Y et al. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells. Blood 90, 1448-1457 (1997).
36. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor g independently of cannabinoid receptors 1 and 2. Mol. Pharmacol. 70, 101-111 (2006).
37. Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K, Sugiura T. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J. Biochem. 135, 517-524 (2004).
38. Mestre L, Correa F, Arevalo-Martin A et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. 92, 1327-1339 (2005).
39. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agro A. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J. Immunol. 166, 7183-7189 (2001).
40. Fischer-Stenger K, Dove Pettit DA, Cabral GA. D9-tetrahydrocannabinol inhibition of tumor necrosis factor-a: suppression of posttranslational events. J. Pharmacol. Exp. Ther. 267, 1558-1565 (1993).
41. Zhu W, Newton C, Dka Y, Friedman H, Klein TW. D9-tetrahydrocannabinol enhances the secretion of interleukin 1 from endotoxin-stimulated macrophages. J. Pharmacol. Exp. Ther. 270, 1334-1339 (1994).
42. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann. Neurol. 65, 239-248 (2009).
43. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol. Ther. 95, 165-174 (2002).
44. Arevalo-Martin A, Garcia-Ovejero D, Gomez O et al. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br. J. Pharmacol. 153, 216-225 (2008).
45. Centonze D, Bari M, Rossi S et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 130, 2543-2553 (2007).
46. Ghosh S, Preet A, Groopman JE, Ganju RK. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol. Immunol. 43, 2169-2179 (2006).
47. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C. T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 36, 220-234 (2001).
48. Aranami T, Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol. Int. 57, 115-120 (2008).
49. Frisullo G, Nociti V, Iorio R et al. IL17 and IFNg production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine 44, 22-25 (2008).
50. Sanchez AJ, Gonzalez-Perez P, Galve-Roperh I, Garcia-Merino A. R-[2,3-dihydro-5-methyl-3-(4- morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4 -benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem. Pharmacol. 72, 1697-1706 (2006).
51. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. 23, 2511-2516 (2003).
52. Mestre L, Docagne F, Correa F et al. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol. Cell Neurosci. 40, 258-266 (2009).
53. Ehrhart J, Obregon D, Mori T et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2, 29 (2005).
54. Correa F, Docagne F, Mestre L et al. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells. Biochem. Pharmacol. 77, 86-100 (2009).
55. Palazuelos J, Davoust N, Julien B et al. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem. 283, 13320-13329 (2008).
56. Sheng WS, Hu S, Min X, Cabral GA, Lokensgard JR, Peterson PK. Synthetic cannabinoid WIN55,212-212 inhibits generation of inflammatory mediators by IL-1b-stimulated human astrocytes. Glia 49, 211-219 (2005).
57. Molina-Holgado F, Molina-Holgado E, Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. 433, 139-142 (1998).
58. Wood JD, Alpers DH, Andrews PL. Fundamentals of neurogastroenterology. Gut 45(Suppl. 2.), II6-II16 (1999).
59. Massa F, Marsicano G, Hermann H et al. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113, 1202-1209 (2004).
60. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 48, 859-867 (2001).
61. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98, 694-702 (1990).
62. Yamada Y, Marshall S, Specian RD, Grisham MB. A comparative analysis of two models of colitis in rats. Gastroenterology 102, 1524-1534 (1992).
63. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281-1290 (1995).
64. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am. J. Physiol. Gastrointest. Liver Physiol. 291, G364-G371 (2006).
65. Izzo AA, Fezza F, Capasso R et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol. 134, 563-570 (2001).
66. Cravatt BF, Demarest K, Patricelli MP et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. USA 98, 9371-9376 (2001).
67. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins Leukot. Essent. Fatty Acids 66, 377-391 (2002).
68. Biecker E, Sagesser H, Reichen J. Vasodilator mRNA levels are increased in the livers of portal hypertensive NO-synthase 3-deficient mice. Eur. J. Clin. Invest. 34, 283-289 (2004).
69. Julien B, Grenard P, Teixeira-Clerc F et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128, 742-755 (2005).
70. Osei-Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115, 1298-1305 (2005).
71. Schwabe RF, Siegmund SV. Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C. Hepatology 42, 975-977 (2005).
72. Teixeira-Clerc F, Julien B, Grenard P et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12, 671-676 (2006).
73. Batkai S, Jarai Z, Wagner JA et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med. 7, 827-832 (2001).
74. Batkai S, Osei-Hyiaman D, Pan H et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 21, 1788 - 1800 (2007).
75. Gary-Bobo M, Elachouri G, Gallas JF et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46, 122-129 (2007).
76. Siegmund SV, Qian T, de Minicis S et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J. 21, 2798-2806 (2007).
77. Hezode C, Roudot-Thoraval F, Nguyen S et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42, 63-71 (2005).
78. Avraham Y, Israeli E, Gabbay E et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol. Dis. 21, 237-245 (2006).
79. Hegde VL, Hegde S, Cravatt BF, Hofseth LJ, Nagarkatti M, Nagarkatti PS. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol. Pharmacol. 74, 20-33 (2008).
80. Hurlimann D, Enseleit F, Ruschitzka F. Rheumatoid arthritis, inflammation, and atherosclerosis. Herz 29, 760-768 (2004).
81. Pratt AG, Isaacs JD, Mattey DL. Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 23, 37-48 (2009).
82. Zurier RB, Rossetti RG, Burstein SH, Bidinger B. Suppression of human monocyte interleukin-1b production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem. Pharmacol. 65, 649-655 (2003).
83. George KL, Saltman LH, Stein GS, Lian JB, Zurier RB. Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J. Cell Physiol. 214, 714-720 (2008).
84. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
85. Malfait AM, Gallily R, Sumariwalla PF et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 97, 9561-9566 (2000).
86. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, Feldmann M. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum. 50, 985-998 (2004).
87. Mamytbekova A, Rezabek K, Kacerovska H, Grimova J, Svobodova J. Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors. Neoplasma 33, 417-421 (1986).
88. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res. 68, 339-342 (2008).
89. Carracedo A, Gironella M, Lorente M et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 66, 6748-6755 (2006).
90. Casanova ML, Blazquez C, Martinez- Palacio J et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 111, 43-50 (2003).
91. Galve-Roperh I, Sanchez C, Cortes ML et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signalregulated kinase activation. Nat. Med. 6, 313-319 (2000).
92. Sanchez C, de Ceballos ML, Gomez del Pulgar T et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61, 5784-5789 (2001).
93. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 65, 1635-1641 (2005).
94. Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, Guzman M. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology 47, 315-323 (2004).
95. Lombard C, Nagarkatti M, Nagarkatti PS. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in D9- tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk. Res. 29, 915-922 (2005).
96. Jia W, Hegde VL, Singh NP et al. D9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol. Cancer Res. 4, 549-562 (2006).
97. McKallip RJ, Lombard C, Fisher M et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634 (2002).
98. Ligresti A, Bisogno T, Matias I et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677-687 (2003).
99. Cianchi F, Papucci L, Schiavone N et al. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor a-mediated ceramide de novo synthesis in colon cancer cells. Clin. Cancer Res. 14, 7691-7700 (2008).
100. Bifulco M, Laezza C, Valenti M et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 18, 1606-1608 (2004).
101. De Lago E, Gustafsson SB, Fernandez- Ruiz J et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J. Neurochem. 99, 677-688 (2006).
102. Endsley MP, Aggarwal N, Isbell MA et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. Int. J. Cancer 121, 984-991 (2007).
103. Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem. Biophys. Res. Commun. 332, 1028-1033 (2005).
104. Contassot E, Tenan M, Schnuriger V, Pelte MF, Dietrich PY. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol. Oncol. 93, 182-188 (2004).
105. Contassot E, Wilmotte R, Tenan M et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J. Neuropathol. Exp. Neurol. 63, 956-963 (2004).
106. DeMorrow S, Glaser S, Francis H et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J. Biol. Chem. 282, 13098-13113 (2007).
107. Bifulco M, Laezza C, Portella G et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15, 2745-2747 (2001).
108. Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C. D9- tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 66, 6615-6621 (2006).
109. Ek S, Hogerkorp CM, Dictor M, Ehinger M, Borrebaeck CA. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res. 62, 4398-4405 (2002).
110. Islam TC, Asplund AC, Lindvall JM et al. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of cyclin D1 in mantle cell lymphoma. Leukemia 17, 1880-1890 (2003).
111. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu. Rev. Immunol. 17, 255-281 (1999).
112. Anderson GP, Coyle AJ. TH2 and 'TH2-like' cells in allergy and asthma: pharmacological perspectives. Trends Pharmacol. Sci. 15, 324-332 (1994).
113. Jan TR, Farraj AK, Harkema JR, Kaminski NE. Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. Toxicol. Appl. Pharmacol. 188, 24-35 (2003).
114. Tashkin DP, Reiss S, Shapiro BJ, Calvarese B, Olsen JL, Lodge JW. Bronchial effects of aerosolized D9-tetrahydrocannabinol in healthy and asthmatic subjects. Am. Rev. Respir. Dis. 115, 57-65 (1977).
115. Abboud RT, Sanders HD. Effect of oral administration of D-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Chest 70, 480-485 (1976).
116. Hartley JP, Nogrady SG, Seaton A. Bronchodilator effect of D1- tetrahydrocannabinol. Br. J. Clin. Pharmacol. 5, 523-525 (1978).
117. Calignano A, Katona I, Desarnaud F et al. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 408, 96-101 (2000).
118. Rajesh M, Mukhopadhyay P, Batkai S et al. Cannabidiol attenuates high glucoseinduced endothelial cell inflammatory response and barrier disruption. Am. J. Physiol. Heart Circ. Physiol. 293, H610-H619 (2007).
119. Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-a-induced human vascular smooth muscle cell proliferation and migration. Br. J. Pharmacol. 153, 347-357 (2008).
120. de Kozak Y, Sakai J, Thillaye B, Faure JP. S antigen-induced experimental autoimmune uveo-retinitis in rats. Curr. Eye Res. 1, 327-337 (1981).
121. Xu H, Cheng CL, Chen M et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH- in a rodent model of autoimmune uveoretinitis. J. Leukoc. Biol. 82, 532-541 (2007).
122. Correa F, Mestre L, Docagne F, Guaza C. Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br. J. Pharmacol. 145, 441-448 (2005).
123. Broderick CA, Smith AJ, Balaggan KS et al. Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis. Mol. Ther. 12, 369-373 (2005).
124. De Kozak Y, Thillaye-Goldenberg B, Naud MC, Da Costa AV, Auriault C, Verwaerde C. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin. Exp. Immunol. 130, 212-223 (2002).
125. Mandrup-Poulsen T. b cell death and protection. Ann. NY Acad. Sci. 1005, 32-42 (2003).
126. Li X, Kaminski NE, Fischer LJ. Examination of the immunosuppressive effect of D9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes. Int. Immunopharmacol. 1, 699-712 (2001).
127. Weiss L, Zeira M, Reich S et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39, 143-151 (2006).
128. Weiss L, Zeira M, Reich S et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54, 244-249 (2008).
129. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am. J. Pathol. 168, 235-244 (2006).
130. Dogrul A, Gul H, Yildiz O, Bilgin F, Guzeldemir ME. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci. Lett. 368, 82-86 (2004).